GleamWall
中文EN

CTNM Contineum Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1855175 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-6.9%
TTM EPS YoY21.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.8%
ROA-28.3%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.5%
Debt / equity0.00x
Current ratio31.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$15.98M$12.70M$11.65M$12.76M$10.99M$14.06M$13.71M$13.02M
SG&A expense$4.98M$4.73M$5.26M$4.36M$3.94M$3.84M$4.40M$4.03M
Operating income-$20.97M-$17.43M-$16.90M-$17.11M-$14.93M-$17.90M-$18.11M-$17.05M
Interest expense———————$0
Pretax income———————-$14.56M
Income tax———————$0
Net income-$18.70M-$15.15M-$14.46M-$15.16M-$12.79M-$16.04M-$15.99M-$14.56M
EBITDA-$20.89M-$17.29M-$16.82M-$17.03M-$14.85M-$17.82M-$18.03M-$16.97M
EPS (basic)-0.49-0.40-0.39—-0.45-0.62-0.62—
EPS (diluted)-0.49-0.40-0.39—-0.45-0.62-0.62—
Weighted avg. shares (diluted)38.39M37.47M37.34M—28.12M25.90M25.87M—
Balance sheet
Cash & equivalents$75.20M$14.71M$20.16M$75.60M$42.63M$20.78M$22.47M$21.94M
Short-term investments$169.29M$221.84M$226.17M$187.29M$139.77M$154.70M$168.24M$182.82M
Current assets$249.74M$242.58M$252.96M$267.92M$184.93M$176.84M$192.13M$206.39M
PP&E, net$848,000$929,000$1.06M$830,000$880,000$856,000$891,000$989,000
Total assets$256.99M$250.37M$261.35M$276.64M$190.85M$182.89M$198.26M$212.85M
Current liabilities$8.03M$6.53M$6.66M$9.74M$6.36M$7.21M$8.95M$9.97M
Total liabilities$11.57M$10.71M$11.31M$15.65M$10.38M$11.50M$13.50M$14.78M
Shareholders' equity$245.42M$239.66M$250.04M$260.99M$180.47M$171.39M$184.77M$198.07M
Cash flow statement
Operating cash flow-$11.06M-$11.50M-$16.27M-$13.04M-$12.20M-$15.66M-$14.41M-$10.20M
Capital expenditure$0$6,000$312,000$42,000$98,000$44,000$47,000$166,000
Free cash flow-$11.06M-$11.51M-$16.58M-$13.08M-$12.29M-$15.71M-$14.46M-$10.37M
Investing cash flow$50.95M$4.85M-$39.31M-$47.45M$14.94M$13.88M$14.91M-$9.39M
Financing cash flow$20.59M$1.20M$129,000$93.47M$19.11M$91,000$24,000$642,000
Depreciation & amortization$81,000$134,000$83,000$85,000$81,000$79,000$78,000$75,000
Stock-based compensation$4.86M$3.84M$3.82M$2.48M$2.57M$2.42M$2.57M$2.25M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.